⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477991 | 0.92 | — | — | |
| SCHEMBL1039009 | 0.85 | — | — | |
| SCHEMBL26166 | 0.85 | — | — | |
| SCHEMBL477826 | 0.83 | — | — | |
| SCHEMBL2533604 | 0.81 | — | — | |
| SCHEMBL63204 | 0.74 | — | — | |
| SCHEMBL575107 | 0.74 | — | — | |
| SCHEMBL6442980 | 0.74 | — | — | |
| SCHEMBL24211192 | 0.71 | ALDH1A1 (0.36) | — | |
| SCHEMBL22790683 | 0.71 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617226-B2 | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (GB) | 2017-04-11 | — | — | US | disclosed |
| US-20160068494-A1 | FUSED HETEROCYCLIC OR CARBOCYCLIC COMPOUNDS CARRYING A SUBSTITUTED CYCLOALIPHATIC RADICAL AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-03-10 | — | — | US | disclosed |
| EP-1642898-B1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD KK (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-1633733-B1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES FOUNDATION (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20070167514-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSTIY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-19 | — | — | US | disclosed |
| EP-1633733-A4 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7169942-B2 | agonists or antagonists; treatment for neuroinflammatory pathologies involving demyelinization, viral encephalitis, cerebrovascular accidents, cranial trauma, ocular disorders, pulmonary disorders, allergic diseases, inflammatory conditions, immune system disorders, central nervous system diseases, etc. | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1633733-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004113320-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-12-02 | — | — | US | disclosed |